Skip to main content
x

Recent articles

ESMO 2025 – little solace for Roche’s doomed TIGIT

A quartet of failed tiragolumab trials featured at ESMO over the weekend.

ESMO 2025 – more ivonescimab shots on goal for Summit

Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.

ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on

The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.

ESMO 2025 – domvanalimab flies the flag for TIGIT

Full data from Edge-Gastric are presented at ESMO.

ESMO 2025 – Tubulis keeps the NaPi2b dream alive

The first TUB-040 data come just after Tubulis raised €308m.

ESMO 2025 – J&J brings a new Rybrevant use into the fold

After promising early data in head and neck, J&J plans a new phase 3, Origami-5.